Regnase-1 overexpression as a therapeutic approach of Marfan syndrome

Marie Noormalal1, Nesrin Schmiedel1, Tarik Bozoglu2

  • 1Department of Internal Medicine III, University of Kiel, and German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.

Insights

Gene therapy using adeno-associated virus (AAV) to overexpress Regnase-1 shows promise for treating Marfan syndrome. This approach reduces inflammation and aortic degradation, potentially preventing fatal aortic aneurysms.

Area of Science:

  • Cardiovascular Biology
  • Gene Therapy
  • Molecular Medicine

Background:

  • Thoracic aortic aneurysms are a leading cause of death in Marfan syndrome.
  • Inflammation and matrix metalloproteinase (MMP)-mediated digestion drive aortic wall remodeling.

Purpose of the Study:

  • To investigate the protective potential of adeno-associated virus (AAV)-mediated vascular Regnase-1 overexpression against aortic aneurysms in Marfan syndrome.

Main Methods:

  • In vitro assessment of Regnase-1 effects on aortic smooth muscle cells.
  • In vivo studies using a Marfan syndrome mouse model with vascular-targeted AAV vector delivery.
  • Analysis of inflammatory markers, MMP activity, elastin degradation, and aortic diameter.

Main Results:

  • Regnase-1 overexpression reduced inflammation and elastin degradation in vitro.
  • AAV-mediated Regnase-1 delivery effectively transduced the aortic wall in vivo.
  • This led to decreased circulating proinflammatory cytokines, reduced MMPs, improved elastin architecture, and smaller aortic diameters.

Conclusions:

  • AAV-mediated Regnase-1 overexpression demonstrates significant protective effects against aortic aneurysm development and progression in a Marfan syndrome model.
  • This approach holds potential as a novel gene therapy strategy for Marfan syndrome-associated aortic disease.